A pilot randomized trial of oxandrolone in inclusion body myositis

Neurology

Volumn 58, Issue 7, 2002, Pages 1081-1087

  Rutkove, S B ^a,b   Parker, R A ^b   Nardin, R A ^a   Connolly, C E ^b   Felice, K J ^c   Raynor, E M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANDROGEN; IMMUNOMODULATING AGENT; OXANDROLONE; PLACEBO;

AGED; ARM MUSCLE; ARTICLE; CLIMBING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; INCLUSION BODY MYOSITIS; MALE; MUSCLE ISOMETRIC CONTRACTION; MUSCLE STRENGTH; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASK PERFORMANCE; TREATMENT OUTCOME; VOLUNTARY MOVEMENT;

EID: 0037046195     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.58.7.1081     Document Type: Article

References (23)

1. Polymyositis, dermatomyositis and inclusion-body myositis
2. Inclusion body myositis and myopathies
3. Mononuclear cells in myopathies: Quantitation of functionally distinct subsets, recognition of antigen specific cell-mediated cytotoxicity in some diseases, and implication for the pathogenesis of the different inflammatory myopathies
4. The treatment of inclusion body myositis: A retrospective review and a randomized, prospective trial of immunosuppressive therapy
5. Inclusion body myositis: Analysis of 32 cases
6. Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study
7. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM
8. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis
9. Inclusion body myositis: Explanation for poor response to immunosuppressive therapy
10. Synergistic effect of beta-amyloid protein and interferon gamma on nitric oxide production by C2C12 muscle cells
11. Sporadic inclusion body myositis correlates with increased expression and cross-linking by transglutaminases 1 and 2
12. Amyloid-beta deposition in skeletal muscle of transgenic mice: Possible model of inclusion body myopathy
13. Does overexpression of betaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer's disease? Clues from inclusion body myositis, cultured human muscle, and transgenic mice
14. Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging
15. Ubiquitin expression in inclusion body myositis. An immunohistochemical study
16. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
17. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men
18. A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: A pilot study
19. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy
20. Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis
21. Body fat assessed from total body density and its estimation from skinfold thickness: Measurements on 481 men and women aged from 16 to 72 years
22. Longitudinal data analysis for discrete and continuous outcomes